• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Merck

Merck

Merck & Co Inc MRK

Last Price$61.49Day Change (%)-0.57%
Open Price$61.77Day Change ($)-0.35
Day Range61.16–61.8252-Week Range58.29–66.80

As of Fri 8/18/2017 7:59:00 PM | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. UPDATE: Merck CEO quits presidential council after Charlottesville violence 'as a matter of personal conscience,' and Trump attacks him

    UPDATE: Merck CEO quits presidential council after Charlottesville violence 'as a matter of personal conscience,' and Trump attacks him

  2. UPDATE: Merck CEO quits presidential council after Charlottesville violence 'as a matter of personal conscience,' and Trump attacks him

    UPDATE: Merck CEO quits presidential council after Charlottesville violence 'as a matter of personal conscience,' and Trump attacks him

  3. Merck Announces Second-Quarter 2017 Financial Results

    Merck Announces Second-Quarter 2017 Financial Results

  4. Merck expects June cyberattack to affect company's 2017 financial performance

    Merck expects June cyberattack to affect company's 2017 financial performance

  5. Merck KGaA 2Q 2017 -- Forecast

    Merck KGaA 2Q 2017 -- Forecast

  6. Global Urinary Tract Infection Treatment Market to Grow at a CAGR of 2.1% by 2021: Key Vendors are Merck , Bayer, Johnson & Johnson, and Novartis - Research and Markets

    Global Urinary Tract Infection Treatment Market to Grow at a CAGR of 2.1% by 2021: Key Vendors are Merck , Bayer, Johnson & Johnson, and Novartis - Research and Markets

  7. Merck Announces Week 96 Results from ONCEMRK, A Study Evaluating Once-Daily ISENTRESS® HD (raltegravir), in Combination with Other Antiretroviral Agents, for the Treatment of HIV-1 Infection in ...

    Merck Announces Week 96 Results from ONCEMRK, A Study Evaluating Once-Daily ISENTRESS® HD (raltegravir), in Combination with Other Antiretroviral Agents, for the Treatment of HIV-1 Infection in Appropriate Patients

  8. Merck Announces Fourth-Quarter 2017 Dividend

    Merck Announces Fourth-Quarter 2017 Dividend

  9. AstraZeneca and Merck Establish Strategic Oncology Collaboration

    AstraZeneca and Merck Establish Strategic Oncology Collaboration

  10. Merck Provides Update on Phase 3 Study of KEYTRUDA® (pembrolizumab) Monotherapy in Patients with Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

    Merck Provides Update on Phase 3 Study of KEYTRUDA® (pembrolizumab) Monotherapy in Patients with Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

12345

©2017 Morningstar Advisor. All right reserved.